Professor/Dr. Wei-Ping Min  Univers

Professor/Dr. Wei-Ping Min 













University of Western Ontario
1151 Richmond Street North B & G 270
London, Ontario N6A 5B7
Canada


Company Description: Western's School of Communication Sciences and Disorders, part of the Faculty of Health Sciences, is home to one of Canada's largest graduate programs in the fields... more






Background




Employment History


Member, Department of Surgery, Microbiology and Immunology

University of Western Ontario


Leading Expert In the Induction of Immunological Tolerance

Medistem Laboratories , Inc.





39 Total References
Web References


comingup
www.immunet.med.ualberta.ca, 26 June 2013 [cached]
Speaker: Dr. Wei-Ping Min, Assistant Professor, University of Western Ontario


:BMSN), announced today it has purchased ...
www.bioresearchonline.com, 6 May 2013 [cached]
:BMSN), announced today it has purchased patent #8,389,708 from Professor Wei-Ping Min of the University of Western Ontario, London, Canada.
...
In the patent and previous publication, Dr. Min and his team demonstrated that by blocking function of IDO, tumors would enter remission.
"My laboratory is looking forward to working with Bio-Matrix Scientific's Regen BioPharma towards advancing our new method of treating cancer from mice to people," stated Dr. Wei-Ping Min, Professor at the University of Western Ontario.

International Workshop on Science and Technology Developments Relevant to the Biological and Toxin Weapons Convention
www.royalsociety.ac.uk, 7 Feb 2007 [cached]
Dr Wei-Ping Min, Department of Surgery, Microbiology and Immunology, University of Western Ontario, Canada


Repair Stem Cell Resources | Stem Cell Information and Articles | Repair Stem Cells.org
www.RepairStemCells.org, 7 Feb 2012 [cached]
The studies, which were led by Dr. Wei-Ping Min of the University of Western Ontario, were published in the "Journal of Translational Medicine" on the 31st January 2012(1).
...
"In the current paper, Dr. Min expanded these studies to a disease-relevant model, and using stem cell-derived dendritic cells was capable of developing promising preclinical data relevant to rheumatoid arthritis."
...
"Medistem is the first company to take a stem cell from discovery to clinical trials in the short span of four years," said Dr. Weiping Min.

Collaborators - Medistem, Inc.
www.medisteminc.com, 12 July 2010 [cached]
Dr. Wei-Ping Min
...
Dr. Wei-Ping Min University of Western Ontario
Dr. Min is a leading expert in the induction of immunological tolerance. Dr Min's group at the University of Western Ontario in London Canada has published extensively with Medistem scientists and is currently collaborating at inducing generation of T regulatory cells with various Medistem protocols. Dr. Min will use the ERC population for inhibition of rheumatoid arthritis in the collagen II-induced model. Dr. Min and Medistem scientists have a paper in press describing this finding.